Compared to patients adherent to monthly injectable buprenorphine, patients on other MOUD (adherent and non-adherent) were 3.5 to 8.1x more ...
Credit: Getty Images. The resubmitted NDA was in response to a Complete Response Letter issued by the FDA in December 2021. The Food and Drug Administration (FDA) has accepted the resubmitted New Drug ...
Please provide your email address to receive an email when new articles are posted on . Brixadi is the first long-acting buprenorphine injectable that is available in weekly and monthly doses.
These are common-sense steps that will be good for orphan drug policy, good for public health, and good for the millions of Americans with opioid use disorder. In a previous post, we described an ...
LUND, Sweden, June 25, 2024 /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) today announced the publication in JAMA Network Open of a new post hoc analysis from a 24-week randomized, double-blind, Phase 3 ...
SLOUGH, England and RICHMOND, Va., Dec. 2, 2019 /PRNewswire/ -- Indivior PLC (LON: INDV) announced today that new analysis from a 12-month investigation of monthly buprenorphine extended-release ...
The trial, published in JAMA Internal Medicine, showed that mothers using the extended-release injection had higher rates of staying off illicit opioids compared to those taking daily sublingual ...
OAKLAND — Dr. Andrew Herring has a clear goal walking into every appointment with patients seeking medication to treat an opioid use disorder: persuade them to get an injection of extended-release ...
The US Food and Drug Administration (FDA) has approved extended-release injection buprenorphine (Brixadi, Braeburn Inc) for the treatment of moderate to severe opioid use disorder (OUD). The ...
Credit: Getty Images. Brixadi (buprenorphine) is an investigational, extended-release weekly and monthly subcutaneous injection for moderate to severe opioid use disorder. The Food and Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results